PharmaMar, S.A.
http://www.pharmamar.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PharmaMar, S.A.
Freeline, Wugen & Jnana Secure EMA PRIME Designations For Novel Treatments
A one-time gene therapy candidate for Gaucher disease, an allogeneic CAR-T cell therapy for difficult-to-treat blood cancers, and a potentially first-in-class drug for treating hyperphenylalaninemia have made it onto the European Medicines Agency’s priority medicines scheme.
BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024
As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines
China Biotech Podcast: AACR, BIOSECURE European Perspectives
Guest Andrew McConaghie from Scrip's UK team joins Brian Yang and Dexter Yan to discuss AACR highlights from Chinese biotechs, European perspectives on the proposed US BIOSECURE Act, two recent acquisitions and Boehringer Ingelheim's recent quarterly results.
AACR: Akeso’s Cadonilimab Shows 1L Potential In Adenocarcinoma
With a clinical win in the Phase III COMPASSION-15 trial in gastric/gastroesophageal junction adenocarcinoma, Akeso's PD-1/CTLA-4-targeting agent is well positioned to expand its label beyond second- or third-line use for cervical cancer, and appears to stack up well against big global competitors. The Chinese firm is also aiming the bispecific antibody at hepatocellular and lung cancers.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Grupo Zeltia
- PharmaMar
- Zeltia Group
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice